HUP0103346A2 - Készítmény és eljárás péniszerekció diszfunkció kezelésére - Google Patents

Készítmény és eljárás péniszerekció diszfunkció kezelésére

Info

Publication number
HUP0103346A2
HUP0103346A2 HU0103346A HUP0103346A HUP0103346A2 HU P0103346 A2 HUP0103346 A2 HU P0103346A2 HU 0103346 A HU0103346 A HU 0103346A HU P0103346 A HUP0103346 A HU P0103346A HU P0103346 A2 HUP0103346 A2 HU P0103346A2
Authority
HU
Hungary
Prior art keywords
composition
mixture
amount
erectile dysfunction
components
Prior art date
Application number
HU0103346A
Other languages
English (en)
Inventor
Robert J. Gyurik
Scott F. Krauser
Carlos M. Samour
Original Assignee
Macrochem Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corporation filed Critical Macrochem Corporation
Publication of HUP0103346A2 publication Critical patent/HUP0103346A2/hu
Publication of HUP0103346A3 publication Critical patent/HUP0103346A3/hu
Publication of HU224318B1 publication Critical patent/HU224318B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya készítmény helyi alkalmazásra olyan személyekpéniszére, akiknek erre szükségük van, amely készítmény (a)prosztaglandin E1 farmakológiailag hatásos mennyiségét; (b) egy C6-C20szénhidrogéncsoporttal helyettesített 1,3-dioxánokból, 1,3-dioxolánokból és acetálokból álló csoportból kiválasztott,bőrbehatolást fokozó vegyület behatolást fokozó mennyiségét; (c) egygyógyszerészetileg hatékony vivőanyagot, amely (i) etilalkohol és víz,az (a) és (b) komponenseket szolubilizáló keveréke; (ii)izopropilalkohol és víz, az (a) és (b) komponenseket szolubilizálókeveréke; vagy (iii) egy olyan keverék lehet, amely az etilalkohol,izopropilalkohol közül legalább egyet és propilénglikolt tartalmaz; és(d) egy sűrítőszer sűrítő hatású mennyiségét; és adott esetben (e)mentol irritáció ellen hatékony mennyiségét tartalmazza. Ó
HU0103346A 1998-06-15 1998-06-15 Készítmény és eljárás péniszerekció diszfunkció kezelésére HU224318B1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/012284 WO1999065303A1 (en) 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunction

Publications (3)

Publication Number Publication Date
HUP0103346A2 true HUP0103346A2 (hu) 2002-01-28
HUP0103346A3 HUP0103346A3 (en) 2004-06-28
HU224318B1 HU224318B1 (hu) 2005-07-28

Family

ID=22267309

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103346A HU224318B1 (hu) 1998-06-15 1998-06-15 Készítmény és eljárás péniszerekció diszfunkció kezelésére

Country Status (18)

Country Link
US (1) US5942545A (hu)
EP (1) EP1026947B1 (hu)
JP (1) JP3513764B2 (hu)
KR (1) KR20010022296A (hu)
CN (1) CN1206998C (hu)
AT (1) ATE209856T1 (hu)
AU (1) AU764437B2 (hu)
BR (1) BR9811797A (hu)
CA (1) CA2296373C (hu)
DE (1) DE69802838T2 (hu)
DK (1) DK1026947T3 (hu)
ES (1) ES2170503T3 (hu)
HK (1) HK1030133A1 (hu)
HU (1) HU224318B1 (hu)
IL (1) IL134191A0 (hu)
NO (1) NO20000157L (hu)
PL (1) PL189436B1 (hu)
WO (1) WO1999065303A1 (hu)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
FR2789586A1 (fr) * 1999-02-16 2000-08-18 Synthelabo Composition pharmaceutique pour administration transmucosale balanique d'alfuzosine
AU3713600A (en) * 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
MXPA01008955A (es) 1999-03-05 2002-04-24 Procter & Gamble Analogos de prostaglandinas selectivas de fp no saturadas de c16.
AU5957600A (en) * 1999-07-30 2001-02-19 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6582683B2 (en) 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100402334B1 (ko) * 2000-06-23 2003-10-22 환인제약 주식회사 알프로스타딜 외용제
WO2002007757A2 (en) 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US6949526B2 (en) * 2000-07-31 2005-09-27 Ono Pharmaceutical Co., Ltd. Erectile dysfunction remedies containing prostaglandin derivatives as the active ingredient
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
KR100649860B1 (ko) * 2000-09-01 2006-11-24 주식회사종근당 알프로스타딜 경점막 및 경피흡수제제
KR20020020536A (ko) * 2000-09-09 2002-03-15 장우영 발기유발제
KR100373540B1 (ko) * 2000-09-20 2003-02-25 최한곤 프로스타글란딘 ｅ1용 요도좌제 조성물
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
CN100581544C (zh) * 2001-03-05 2010-01-20 美国医疗产品公司 用于***机能障碍治疗和逆转的可注射药物组合物
HU225597B1 (en) * 2001-03-30 2007-05-02 Futura Medical Dev Ltd Condom with an erectogenic compound or composition and use of an erectogenic compound or composition for the manufacture of a medicament and use of an erectogenic compound for preparation of a composition
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US6756059B2 (en) 2001-08-20 2004-06-29 Skinvisible Pharmaceuticals, Inc. Topical composition, topical composition precursor, and methods for manufacturing and using
US7041305B2 (en) * 2001-09-07 2006-05-09 Western Holdings, Llc Stable water in oil aminophylline emulsions
KR100446960B1 (ko) * 2001-12-04 2004-09-01 김종국 프로스타글란딘 ｅ1을 포함하는 온도감응성 에멀젼 외용제조성물
KR100810404B1 (ko) * 2001-12-18 2008-03-04 환인제약 주식회사 알프로스타딜 알킬 에스테르를 함유하는 외용제 조성물
US6673841B2 (en) 2001-12-20 2004-01-06 Whan In Pharm. Co., Ltd. Alprostadil alkyl ester-containing composition for external application
US20030220292A1 (en) * 2002-02-15 2003-11-27 Nexmed (Holdings), Inc. Treatment of erectile dysfunction
US6919348B2 (en) 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20040126339A1 (en) * 2002-12-31 2004-07-01 Roszell James A. Sunscreen composition and methods for manufacturing and using a sunscreen composition
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
KR101086147B1 (ko) 2003-03-21 2011-11-25 넥스메드 홀딩스 인코포레이티드 조루증 치료용 조성물 및 치료 방법
JP2006520788A (ja) * 2003-03-21 2006-09-14 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物による血管形成促進および方法
JP2006522136A (ja) * 2003-04-02 2006-09-28 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物および血管痙攣の治療のためのその使用
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
BRPI0418589A (pt) 2003-12-08 2008-01-29 Bentley Pharmaceuticals Inc composições farmacêuticas e métodos para tratamento por insulina
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US20100137333A1 (en) * 2006-10-20 2010-06-03 Roszell James A Antifungal composition and methods for using
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US8128913B1 (en) 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
BRPI0800596A2 (pt) 2008-01-31 2009-09-22 Univ Minas Gerais método para a potencialização da função erétil através do uso das composições farmacêuticas de toxina tx2-6 da aranha phoneutria nigriventer
US8299122B2 (en) * 2008-04-14 2012-10-30 Skinvisible Pharmaceuticals, Inc. Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
CA2838109C (en) 2011-04-07 2020-06-09 Nexmed Holdings, Inc. Topical semisolid prostaglandin e1 composition for treating raynaud's disease
MX2022007009A (es) * 2019-12-09 2022-08-25 Futura Medical Developments Ltd Composicion topica y metodos de medicion de la capacidad de refrigeracion de una composicion.
CA3074150A1 (en) 2020-02-18 2021-08-18 Ovation Science, Inc. Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc)
EP4232002A1 (en) * 2020-10-22 2023-08-30 Standard International Group Holdings, LP Transdermal treatment for erectile dysfunction

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
IT1252603B (it) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
IT1247678B (it) * 1990-05-31 1994-12-28 Alberto Reale Metodo per la cura dell'impotenza erettiva maschile
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
WO1993012788A1 (en) * 1991-12-23 1993-07-08 The Upjohn Company Pyridylguanidine compounds for treatment of erectile dysfunction
DE69320378T2 (de) * 1992-01-21 1999-04-29 Macrochem Corp Iontophoretische verbesserte Verabreichung von Medikamenten
US5400094A (en) * 1993-03-31 1995-03-21 Minnesota Mining And Manufacturing Company Condensers for overhead projectors
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5587167A (en) * 1993-09-14 1996-12-24 Choi; Hyung K. Pharmaceutical composition for prophylaxis and treatment of premature ejaculation
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5451609A (en) * 1994-07-27 1995-09-19 Institut De Recherches Chimiques Et Al Treatment of impotence
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5620980A (en) * 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin

Also Published As

Publication number Publication date
JP3513764B2 (ja) 2004-03-31
NO20000157L (no) 2000-02-09
JP2000511944A (ja) 2000-09-12
US5942545A (en) 1999-08-24
DE69802838D1 (de) 2002-01-17
PL189436B1 (pl) 2005-08-31
DE69802838T2 (de) 2002-06-27
NO20000157D0 (no) 2000-01-12
PL338787A1 (en) 2000-11-20
DK1026947T3 (da) 2002-04-02
EP1026947A1 (en) 2000-08-16
AU7838798A (en) 2000-01-05
AU764437B2 (en) 2003-08-21
HUP0103346A3 (en) 2004-06-28
BR9811797A (pt) 2000-09-26
CN1206998C (zh) 2005-06-22
EP1026947A4 (en) 2000-10-25
CA2296373A1 (en) 1999-12-23
EP1026947B1 (en) 2001-12-05
HK1030133A1 (en) 2001-04-27
IL134191A0 (en) 2001-04-30
CA2296373C (en) 2003-08-12
CN1267191A (zh) 2000-09-20
ES2170503T3 (es) 2002-08-01
ATE209856T1 (de) 2001-12-15
HU224318B1 (hu) 2005-07-28
KR20010022296A (ko) 2001-03-15
WO1999065303A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
HUP0103346A2 (hu) Készítmény és eljárás péniszerekció diszfunkció kezelésére
ES2141950T3 (es) Composiciones que contienen troxerutina complejada con fosfatidilcolina para el tratamiento topico de la impotencia erectil.
HUP0101543A2 (hu) Női szexuális zavarok kezelésére szolgáló gyógyszerkészítmények
GEP20063982B (en) Use of prostaglandin compositions with male persons for treatment of erectile dysfunction
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
EA200001043A2 (ru) Соединения для лечения женской сексуальной дисфункции
DK1115384T3 (da) Fentanyl-præparat til behandling af akutte smerter
DK0880350T3 (da) Behandling af dissemineret sklerose
PT1137409E (pt) Composicoes e metodos para melhoramento da disfuncao sexual feminina humana
PT1100516E (pt) Extratos de matricaria (tanacetum parthenium) contra doencas inflamatorias
BR9509807A (pt) Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3
DK0526566T3 (da) Behandling af erektil dysfunktion
EA200400007A1 (ru) ФАРМАЦЕВТИЧЕСКИЙ СОСТАВ ДЛЯ ЭФФЕКТИВНОГО ВВЕДЕНИЯ АПОМОРФИНА, 6aR-(-)-N-ПРОПИЛ-НОРАПОМОРФИНА, ИХ ПРОИЗВОДНЫХ И ИХ ПРОЛЕКАРСТВ
HUP0102728A2 (hu) Módszerek és transzdermális készítmények fájdalom csillapítására
KR950031060A (ko) 골다공증 치료용 약제학적 조성물
ES2221950T3 (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
CY1108631T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια στυτικης δυσλειτουργιας των ανδρων
HUP0104413A2 (hu) Ascomycineket tartalmazó helyi készítmények
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
AR019327A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
HK1068003A1 (en) Pharmaceutical composition comprising gamma-butyrobetaine
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
ES2169942T3 (es) Uso de preparaciones topicas de trinitrato de glicerilo y lanolina para el tratamiento de la disfuncion erectil.
BE894860A (fr) Therapeutique adjuvante par agent progestatif

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050613

MM4A Lapse of definitive patent protection due to non-payment of fees